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Summary
Management of young women with breast cancer is complex and has several particularities, one of which is fertility 
preservation, a very important quality of life issue for young breast cancer survivors. Chemotherapy can be gonadotoxic 
and signifi cantly reduce woman`s reproductive potential and cause premature ovarian insuffi  ciency while endocrine ther-
apy requires a delay of pregnancy and indirectly aff ects fertility. Therefore every woman of reproductive age diagnosed 
with breast cancer should be informed about potential gonadotoxic eff ect of cancer treatment, the risk of premature ovarian 
insuffi  ciency and associated symptoms, available fertility preservation methods, delay of cancer treatment and chances of 
subsequent pregnancy. If interested in fertility preservation breast cancer patients should be referred as early as possible to 
a reproductive specialist to further discuss the risk of infertility and available fertility preservation options. Currently estab-
lished methods for fertility preservation are embryo and oocyte cryopreservation, while ovarian tissue cryopreservation, 
cryopreservation of immature oocytes and ovarian suppression with gonadotropin-releasing hormone agonists are still 
considered experimental.
The aim of this review is to highlight the importance of fertility preservation as an important quality of life issue for 
young breast cancer survivors.
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LIJEČENJE MLADIH ŽENA S RANIM STADIJEM RAKA DOJKE - VAŽNOST OČUVANJA PLODNOSTI
Sažetak
Liječenje mladih žena s rakom dojke je složeno i ima nekoliko posebnosti, jedna od kojih je očuvanje plodnosti, vrlo 
bitan čimbenik kvalitete života mladih žena koje su preboljele rak dojke. Kemoterapija može štetno utjecati na jajnike i zna-
čajno smanjiti reprodukcijski potencijal žene i uzrokovati prijevremenu ovarijsku insufi cijenciju, dok endokrina terapija 
zahtijeva odgodu trudnoće i tako posredno utječe na plodnost. Stoga bi svaka žena, kojoj je rak dojke dijagnosticiran u re-
produkcijskoj dobi, trebala biti informirana o mogućem gonadotoksičnom učinku antineoplastičke terapije, riziku prijevre-
mene ovarijske insufi cijencije i povezanim simptomima, dostupnim metodama očuvanja plodnosti, odgodi sustavne antine-
oplastičke terapije, kao i o mogućnostima ostvarenja trudnoće nakon provedenog liječenja. Ukoliko je bolesnica s rakom 
dojke zainteresirana za očuvanje plodnosti, treba je što ranije uputiti subspecijalistu humane reprodukcije, koji će joj dodat-
no objasniti rizike za neplodnost i dostupne metode očuvanja plodnosti. Krioprezervacija embrija i oocita su trenutno jedine 
etablirane metode očuvanja plodnosti, dok se krioprezervacija tkiva jajnika, krioprezervacija nezrelih oocita i ovarijska su-
presija još uvijek smatraju eksperimentalnima.
Cilj ovoga preglednog rada je istaknuti važnost očuvanja plodnosti kao bitnog čimbenika kvalitete života mladih žena 
koje su preboljele rak dojke.




Advances in the breast cancer (BC) treatment 
have increased survival rates of BC patients. One 
of the most important survivorship issues for 
young BC patient is fertility preservation because 
cancer treatment can be gonadotoxic and reduce 
the reproductive potential of young women. 
Breast cancer therapy can aff ect fertility both di-
rectly with administration of gonadotoxic chemo-
therapy to ovaries and indirectly in case of HR-
positive BC with the administration of endocrine 
therapy. Because of teratogenic potential of endo-
crine therapy, pregnancy is contraindicated dur-
ing 5 year or longer period of this therapy (1). Data 
suggest that young women have unique biology 
and more aggressive phenotypes of BC. However, 
according to current recommendations the same 
factors should be taken into account for older and 
young BC patients for decision of which therapy 
to prescribe (2, 3). Younger women are often can-
didates for gonadotoxic chemotherapy and in case 
of HR-positive BC subsequently for endocrine 
therapy. These treatments can signifi cantly impair 
their fertility. The postponement of fertility in 
contemporary societies results in increased num-
ber of young patients diagnosed with BC who 
have not yet completed their family and wish to 
preserve fertility and achieve subsequent preg-
nancy (4).
Pregnancy after breast cancer
Current retrospective evidence suggests that 
pregnancy after BC is not associated with an in-
creased risk of recurrence and should not be dis-
couraged, even in case of HR-positive BC. Al-
though optimal timing for conception after BC is 
unknown, it is suggested that early pregnancy 
(during the fi rst 2 years from BC diagnosis) should 
be avoided. It is recommended to wait 3-6 months 
after treatment interruption and pregnancy at-
tempt to allow wash-out of endocrine therapy. 
Also, there is no evidence supporting a therapeu-
tic role of induced abortion (5, 6, 7, 8, 9).
Currently ongoing prospective POSITIVE 
(Pregnancy Outcome and Safety of Interrupting 
Therapy for Women with Endocrine Responsive 
BC, ClinicalTrials.gov Identifi er: NCT02308085) 
study will att empt to answer a lot of open ques-
tions in the oncofertility fi eld, particularly safety 
of endocrine therapy interruption in HR-positive 
BC. Also, BC patients have increased risks of de-
livery complications (cesarean section, preterm 
delivery and low birth weight) and should be 
closely monitored during pregnancy (8). Patients 
should be strongly advised to avoid pregnancy 
during active cancer treatment due to teratogenic 
potential of both chemotherapy and endocrine 
therapy. Barrier methods such as condoms and 
cervical diaphragm and copper IUDs or male con-
traception are recommended, while hormone con-
traception is contraindicated (5).
Fertility consultation
Young premenopausal BC patients should be 
informed about the biology of BC, proposed 
 treatment options and expected benefi ts, potential 
gonadotoxic eff ect of planned treatment for BC, 
risk of premature ovarian insuffi  ciency (POI) 
and associated symptoms (vasomotor symptoms, 
weight gain, sexual dysfunction, sleep disorders, 
osteoporosis, atherosclerosis) and infertility, avail-
able fertility preservation options, safety and po-
tential timing of subsequent pregnancy, delay of 
cancer treatment initiation and, if interested in fer-
tility preservation, BC patients should be referred 
to a reproductive specialist early as possible to 
further discuss the risk of infertility and available 
options for fertility preservation. A multidisci-
plinary approach to fertility preservation and ear-
ly referral are the key components for the success-
ful fertility preservation which allows young BC 
survivors to have their own biological family in 
the future (8, 10).
Gonadotoxicity is dependent on the age of 
the patient, remaining ovarian reserve, type and 
the dose of planned chemotherapy. Older women 
have a greater risk of POI because they have natu-
rally reduced ovarian reserve. Patients with previ-
ous exposure to gonadotoxic therapy, autoim-
mune disease, endometriosis have increased risk 
of POI (11). Among diff erent chemotherapy agents, 
cyclophosphamide is considered to be the most 
gonadotoxic. Cyclophosphamide is a cell-cycle 
nonspecifi c alkylating agent which causes dam-
age to resting and growing follicles in a dose-de-
pendent manner (12,13). Ovarian reserve can be 
assessed by hormone assays (Anti-Mullerian hor-
mone, follicle-stimulating hormone (FSH), estra-
diol, inhibin-B) and antral follicle count with 





Gold standard methods for fertility preserva-
tion are embryo and mature oocyte cryopreserva-
tion both of which require ovarian stimulation 
(OS) and delay initiation of chemotherapy for at 
least 2 weeks with the use of random start OS pro-
tocols (15, 16, 17). The success of both of these 
methods is highly dependent on the age of the pa-
tients, reproductive history and number of stored 
oocytes or embryos. In order to achieve a suffi  -
cient number of oocytes for cryopreservation pro-
cess OS needs to be performed. Because of con-
cerns that OS would increase signifi cantly estra-
diol levels and increase the risk of BC recurrence 
in HR-positive BC alternative and safer protocols 
for OS using letrozole with gonadotropins were 
developed which are considered to be safe and ef-
fective (18, 19, 20, 21). Reported live birth per em-
bryo transfer is 45% which is comparable to pa-
tients using IVF because of infertility (20).
For those women unable to undergo embryo 
cryopreservation because of law restriction, reli-
gious and ethical reasons, lack of partner or un-
willingness to use sperm donor alternative to em-
bryo cryopreservation is oocyte cryopreservation. 
With the use of vitrifi cation oocyte cryopreserva-
tion has improved live birth rates. Reported live 
birth rate per patient was higher in patients young-
er than 35 years (live birth rate of 50% compared to 
22.9% for women older than 36 years), needing at 
least 8-10 metaphase II oocytes for successful out-
come, with individualization of numbers of oo-
cytes for women older than 36 years (22).
Other fertility preservation methods include 
ovarian tissue cryopreservation, cryopreservation 
of immature oocytes, ovarian suppression with 
gonadotropin-releasing hormone agonists (Gn-
RHa) which are still considered experimental in 
fertility preservation. A great advantage of these 
methods is that they do not require OS and there-
fore can be used in patients who cannot delay start 
of cancer treatment.
Administration of GnRHa is the only non-
invasive fertility preservation procedure which 
does not require the use of assisted reproductive 
technologies, therefore, it is signifi cantly less ex-
pensive than other methods. There has been a lot 
of controversy regarding the use of GnRHa as a 
fertility preservation method. Although exact 
mechanism of action of GnRHa that could protect 
is currently uncertain it has been suggested that 
GnRHa could protect the ovaries from the go-
nadotoxic eff ect of chemotherapy with induction 
of gonadal quiescence and prevention of ovarian 
burnout fenomen, reduction of ovarian blood fl ow 
which could decrease the delivery of chemothera-
py to ovaries as well with the upregulation of an-
tiapoptotic pathways (23). On the contrary others 
stated that primordial follicles do not express go-
nadotropin receptors so GnRHa could not have 
direct eff ect on them and protect ovaries from the 
gonadotoxic eff ect of chemotherapy and pointed 
out that the majority of studies which evaluated 
the effi  cacy of GnRHa did not include adequate 
endpoints to measure fertility (24). Recent meta-
analysis showed that when given concurrently 
with chemotherapy GnRHa resulted in reduced 
risk of POI (OR 0.38; 95% CI 0.26-0.57) which is 
also very important issue for the quality of life of 
young patients taking into consideration all the 
symptoms associated with early menopause. 
Metaanalysis also showed higher chance for sub-
sequent pregnancy; 10.5% in patients who re-
ceived GnRHa, compared to 5.5% of pregnancies 
in control group, incidence rate ratio 1.83; 95% CI, 
1.06 to 3.15 (25). Current ASCO guidelines recom-
mend using GnRHa to reduce the likelihood of 
chemotherapy-induced ovarian insuffi  ciency and 
when other fertility preservation methods such as 
oocyte, embryo or ovarian tissue cryopreservation 
are not available (15).
In vitro maturation (IVM) is a technique 
which involves harvesting of immature oocytes 
from unstimulated ovaries or ovarian tissue are 
maturation in vitro. A high antral count is very 
important for the success of this method. Success 
rates of IVM are much lower compared to stan-
dard IVF, it is more expensive and technically 
more demanding (26, 27).
Ovarian tissue cryopreservation is att ractive 
fertility preservation method in which ovarian tis-
sue is harvested laparoscopically, cryopreserved 
and transplanted back to the patient either into 
pelvis cavity (orthotopic site) or extrapelvic site 
(heterotopic site) when a patient wants to use their 
ovarian tissue. Ovarian tissue cryopreservation 
has the advantage of restoring endocrine function, 
in more than 95% of patients when performed or-
thotopically. More than 130 babies have been born 
using this method with a pregnancy rate of 29%. 
Furthermore, orthotopic transplantation allows 
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spontaneous pregnancy (28). Postt ransplantation 
ischemia is a signifi cant problem for this method 
and the age of the patient should be taken into ac-
count when using this method. Therefore ovarian 
tissue cryopreservation is recommended to pa-
tient younger than 35 years who have good ovari-
an reserve with a real chance of 5-year survival 
who have 50% risk of POI (28). Ovarian tissue 
needs to be examined by histology and molecular 
biological techniques before returned to patient to 
exclude malignant reseeding of cancer cells. Fur-
ther developments in this fi eld to avoid reimplan-
tation of malignant cells include isolation of pri-
mordial follicles and formation of the artifi cial 
ovary (28, 29).
CONCLUSION
Infertility is a devastating adverse conse-
quence whi ch can occur after successful oncologi-
cal treatment and cause a great deal of psycholog-
ical distress and depression for young women 
who have not completed their family prior to BC 
diagnosis. Therefore fertility preservation has 
emerged as a very important quality of life issue 
for these patients. Every woman of reproductive 
age diagnosed with BC should be informed about 
potential adverse eff ect of cancer treatment and its 
eff ect on fertility and, if interested in fertility pres-
ervation, should be early referred to a reproduc-
tive specialist to further discuss the risk of infertil-
ity and available fertility preservation options.
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